Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
INBX•Phase 2 study results for Inbrx-106
Sept. 8 (Reuters) - Inhibrx Biosciences Inc. INBX.O:
- Inhibrx's Inbrx-106 nearly doubles response rate and achieves interim median PFS of 9.6 months in Phase 2 HNSCC study
- Inhibrx Biosciences - Inbrx-106 plus pembrolizumab achieves 48.3% corr and 72.4% six-month PFS rate
- Inhibrx Biosciences - to expand Phase 2 study by 50 HPV+ patients
- Inhibrx Biosciences Inc.: also plans to explore potential of Inbrx-106 in combination with therapeutic cancer vaccines
- Inhibrx Biosciences Inc.: evaluating potential of Inbrx-106 in other highly immunogenic tumor types
- Inhibrx Biosciences: currently conducting Phase 1/2 study of Inbrx-106 in perioperative setting of NSCLC, with initial results targeted by mid-2027
Source text: ID:nPn6J28q4a
Further company coverage: INBX.O
Related News
Relmada Therapeutics says CMO-Urology Raj S. Pruthi departs
RLMD•
Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)
NTLA•
